The role of targeted therapy and biomarkers in breast cancer treatment. - Wikidata - wikimedia - TriplyDB

The role of targeted therapy and biomarkers in breast cancer treatment.

The role of targeted therapy and biomarkers in breast cancer treatment.

http://www.wikidata.org/entity/Q38018259

about

World Endometriosis Research Foundation Endometriosis Phenome and Biobanking Harmonisation Project: IV. Tissue collection, processing, and storage in endometriosis research The marine-derived sipholenol A-4-O-3',4'-dichlorobenzoate inhibits breast cancer growth and motility in vitro and in vivo through the suppression of Brk and FAK signaling.Biocompatible nanopolymers: the next generation of breast cancer treatment?Ganoderiol A-enriched extract suppresses migration and adhesion of MDA-MB-231 cells by inhibiting FAK-SRC-paxillin cascade pathway.Breast cancer "tailored follow-up" in Italian oncology units: a web-based survey.Huaier Extract Induces Autophagic Cell Death by Inhibiting the mTOR/S6K Pathway in Breast Cancer Cells.LETM1 overexpression is correlated with the clinical features and survival outcome of breast cancer.The expression and clinical significance of HERC4 in breast cancer.Breast cancer causes and treatment: where are we going wrong?Clinical implications of high NQO1 expression in breast cancers Somatic alterations as the basis for resistance to targeted therapies.Survival prediction score: a simple but age-dependent method predicting prognosis in patients undergoing palliative radiotherapy.Significance of ERα, HER2, and CAV1 expression and molecular subtype classification to canine mammary gland tumor.GSTT1, GSTP1, and GSTM1 genetic variants are associated with survival in previously untreated metastatic breast cancer.PTENP1 acts as a ceRNA to regulate PTEN by sponging miR-19b and explores the biological role of PTENP1 in breast cancer.The role of the pathology department in the preanalytical phase of molecular analyses.Addition of vasopressin synthetic analogue [V(4)Q(5)]dDAVP to standard chemotherapy enhances tumour growth inhibition and impairs metastatic spread in aggressive breast tumour models.Glutathione S-transferases deletions may act as prognosis and therapeutic markers in breast cancer.

P2860

Q26827259-17764382-6D7C-49E4-A561-6FB310532F1F Q33575622-C81332BE-0932-489D-B5F0-6B0B3CD58D08 Q33864065-B25315AA-C910-4FA5-895D-95A70C402DEC Q35034732-7D82714A-90B4-4794-8425-49498C82A742 Q35143022-39E52025-8EF7-46AA-84CF-87CC7A01D39A Q35680733-BC4C8110-8C2F-4222-80F4-98BA5C9F2E43 Q36375254-5352452B-D33F-4E6A-988B-309AF46AC197 Q37322118-EF5FC4BF-A4F0-408A-BFDC-2A8C154401B7 Q37593526-C628791D-B33C-4780-871B-78FFDBABD9EA Q37621051-3AFEF063-4447-4826-A087-D9FF42BCF4E7 Q38151570-ABFF64F4-3466-43A2-8BCA-ECD928A4114E Q38632096-C64B243C-93A6-4EFB-900A-B45DC2B732D5 Q42457894-5058B6E9-2DCD-4A5F-9B3D-8EB250C27C2C Q47123679-7413C0FB-AEA3-44CF-8460-DF769EEB538B Q50523894-18C082D6-ED44-4C3D-A91F-CCA0178EF1D8 Q52562703-8042A5BB-B279-48B2-8785-5872290A17C8 Q53788180-3F8257C4-BA0D-4D49-8AEA-CD0D5ED72F0D Q54579368-85B16088-C237-4AA7-A996-823146A3351A

P2860

The role of targeted therapy and biomarkers in breast cancer treatment.

http://www.wikidata.org/entity/Q38018259

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

The role of targeted therapy and biomarkers in breast cancer treatment.

@en

type

label

The role of targeted therapy and biomarkers in breast cancer treatment.

@en

prefLabel

The role of targeted therapy and biomarkers in breast cancer treatment.

@en

P1433

Q38018259-8F03B0F0-C26E-4D64-95A8-395CB0561DB9

P1476

Q38018259-D7B50046-CBF1-4DF7-A1E1-E3D29308F7A3

P2093

Q38018259-058B57B6-09E7-4F41-8B33-69FA11E3D703

Q38018259-31A07C04-5B51-4F0C-BAD3-D7F3EA5E32E5

Q38018259-5DC371E1-1756-492F-85EF-7BC6A5DA4C73

Q38018259-676A912A-13C2-442A-BE2A-3C411CFC04C5

Q38018259-6CB9B8E6-303F-4C26-B509-8A839AA06B35

Q38018259-989D5C2F-F788-4FC3-87D7-59261ACE6929

Q38018259-AC4EF088-A0DB-4233-8144-DAF540933A0F

Q38018259-F92956E9-62D2-487E-A800-5A0B27F302B4

P2860

Q38018259-08F68D76-BDF8-4AFE-BCED-109489F007A9

Q38018259-0BDBA33D-D340-41B0-BE7C-D9E093146FD3

Q38018259-0EDCE15F-E14B-4BDF-B1FD-C54D9DFF4673

Q38018259-10785D9F-8BF3-478F-962F-2AD60753D785

Q38018259-11ED051C-9A34-42BE-AE7B-24DA55C4DCDC

Q38018259-1216652D-8FC7-44B9-BE7A-7DDBC66B6865

Q38018259-12B2418A-8287-44E3-AE13-D68C173B072A

Q38018259-13360E96-22E0-4356-9B50-882F869A09C5

Q38018259-16491D71-D016-4DF9-BBE8-EB35EE811CA8

Q38018259-1AD4D11D-4ACE-4AE5-AFC2-DC112C1C4DB6

P2888

Q38018259-80CA3733-DCB9-4F47-A555-09D0DFBEABA4

P304

Q38018259-A7F4BDAE-CB6C-4A1A-A192-42838038ED94

P31

Q38018259-13B8EA14-7A96-4F01-A998-8CDE7E0630FF

P356

Q38018259-374E0AA4-67A5-413F-9267-1EEE3EDBEE0D

P433

Q38018259-0806FF58-852C-4B57-BD53-9B8CFC0DF177

P478

Q38018259-155C8DA2-B7B2-42DC-A530-8E2D49F222DA

P577

Q38018259-FE1F6A21-C4A6-4954-921F-C450ED3ADA31

P6179

Q38018259-A8317306-5CA1-42A6-BF88-4E9F75F17C71

P698

Q38018259-AB5EDD46-45A8-4241-8C6E-B2C0651EEB78

P921

Q38018259-D394FA61-DC8A-4C82-8259-3A2813A3CCB1

P356

S10585-012-9496-Y

P1433

Clinical & Experimental Metastasis

P1476

The role of targeted therapy and biomarkers in breast cancer treatment.

@en

P2093

Alison T Stopeck

http://www.w3.org/2001/XMLSchema#string

Ben Ho Park

http://www.w3.org/2001/XMLSchema#string

Clifford A Hudis

http://www.w3.org/2001/XMLSchema#string

Hong Yuen Wong

http://www.w3.org/2001/XMLSchema#string

Hope S Rugo

http://www.w3.org/2001/XMLSchema#string

Sara E Barnato

http://www.w3.org/2001/XMLSchema#string

Ursa Brown-Glaberman

http://www.w3.org/2001/XMLSchema#string

William J Gradishar

http://www.w3.org/2001/XMLSchema#string

P2860

Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro

Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.

Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer.

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

P2888

s10585-012-9496-y

P304

807-819

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10585-012-9496-Y

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P577

2012-06-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1040153979

http://www.w3.org/2001/XMLSchema#string

P698

22692561

http://www.w3.org/2001/XMLSchema#string

P921